文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Treatment of RA With Anakinra a rhI-1Ra in Combination With Methotrexate
侵权投诉

Treatment of RA With Anakinra a rhI-1Ra in Combination With Methotrexate

ARTHRITIS&RHEUMATISM

Vol.46,No.3,March2002,pp614–624DOI10.1002/art.10141

©2002,AmericanCollegeofRheumatology

TreatmentofRheumatoidArthritisWithAnakinra,aRecombinantHumanInterleukin-1ReceptorAntagonist,

inCombinationWithMethotrexate

ResultsofaTwenty-Four–Week,Multicenter,Randomized,Double-Blind,

Placebo-ControlledTrial

StanleyCohen,1EricHurd,2JohnCush,3MichaelSchiff,4MichaelE.Weinblatt,5

LarryW.Moreland,6JoelKremer,7MorayeB.Bear,8WilliamJ.Rich,8andDorothyMcCabe8

Objective.Toevaluatetheefficacyandsafetyofanakinraincombinationwithmethotrexate(MTX)inpatientswithactiverheumatoidarthritis(RA).

Methods.Patientswithmoderate-to-severeactiveRAwhowerereceivingMTXfor6consecutivemonths,withstabledosesfor>3months(thosewithdiseasedurationof>6monthsbut<12years)wererandomizedinto6groups:placeboor0.04,0.1,0.4,1.0,or2.0mg/kgofanakinraadministeredinasingle,daily,subcutane-ousinjection.TheprimaryefficacyendpointwastheproportionofsubjectswhomettheAmericanCollegeofRheumatology20%improvementcriteria(attainedanACR20response)atweek12.

Results.Atotalof419patientswererandomizedinthestudy.Patientdemographicsanddiseasestatusweresimilarinthe6treatmentgroups.TheACR20responsesatweek12inthe5activetreatmentplusMTXgroupsdemonstratedastatisticallysignificant(P 0.001)dose-responserelationshipcomparedwiththe

SupportedbyagrantfromAmgen,Inc.1

StanleyCohen,MD:St.PaulMedicalCenter,Dallas,Texas;

2

EricHurd,MD:BaylorMedicalCenter,Dallas,Texas;3JohnCush,MD:PresbyterianMedicalCenter,Dallas,Texas;4MichaelSchiff,MD:DenverArthritisClinic,Denver,Colorado;5MichaelE.Wein-blatt,MD:HarvardMedicalSchool,Boston,Massachusetts;6LarryW.Moreland,MD:UniversityofAlabamaatBirmingham;7JoelKremer,MD:AlbanyMedicalCollege,Albany,NewYork;8MorayeB.Bear,MA,MS,WilliamJ.Rich,MS,DorothyMcCabe,PhD:Amgen,Inc.,ThousandOaks,California.

AddresscorrespondenceandreprintrequeststoStanley

Cohen,MD,DepartmentofRheumatology,5939HarryHinesBoule-vard,Suite400,Dallas,TX75235.E-mail:stanleycohen@radiantresearch.com.

SubmittedforpublicationMarch9,2001;acceptedinrevised

formNovember2,2001.

614

ACR20responseintheplaceboplusMTXgroup.TheACR20responserateintheanakinra1.0-mg/kg(46%;P 0.001)and2.0-mg/kg(38%;P 0.007)dosegroupswassignificantlygreaterthanthatintheplacebogroup(19%).TheACR20responsesat24weekswereconsis-tentwiththoseat12weeks.Similarimprovementsinanakinra-treatedsubjectswerenotedinindividualACRcomponents,erythrocytesedimentationrate,onsetofACR20response,sustainabilityofACR20response,andmagnitudeofACRresponse.Anakinrawassafeandwelltolerated.Injectionsitereactionwasthemostfrequentlynotedadverseevent,andthisledtoprematurestudywithdrawalin7%(1.0-mg/kggroup)to10%(2.0-mg/kggroup)ofpatientsreceivinghigherdoses.

Conclusion.Inpatientswithpersistentlyactive

RA,thecombinationofanakinraandMTXwassafeandwelltoleratedandprovidedsignificantlygreaterclinicalbenefitthanMTXalone.

Rheumatoidarthritis(RA)isachronic,progres-sive,systemic,inflammatorydisorderofunknownetiol-ogycharacterizedbysymmetric,erosive,anddisablingpolyarthritisandawidearrayofextraarticularcompli-cations.Asthediseaseprogresses,irreversiblejointdamagemayleadtolossoffunctionandtodeformity.Long-termstudieshavedemonstratedthatsignificantdisabilityoccursin50–70%ofpatientsafter10–15yearsofdisease(1).

Twoofthemostimportantdiscoveriesinthelast

decadeofRAresearchare1)jointdestructionoccursearlyinthecourseofthedisease,and2)cytokinesare

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email